TD Asset Management Inc Makes New $730,000 Investment in Edgewise Therapeutics, Inc. (NASDAQ:EWTX)

Key Points

• TD Asset Management Inc has invested approximately $730,000 in Edgewise Therapeutics, acquiring 33,200 shares during the 1st quarter.
• Edgewise Therapeutics' shares are currently down 4.9%, with a market cap of $1.43 billion and a reported earnings per share of ($0.43).
• Various institutional investors have modified their positions in Edgewise, with Skandinaviska Enskilda Banken AB investing around $827,000 in the same period.

TD Asset Management Inc acquired a new stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 33,200 shares of the company's stock, valued at approximately $730,000.

A number of other institutional investors have also recently bought and sold shares of the business. Diadema Partners LP bought a new position in shares of Edgewise Therapeutics in the fourth quarter worth $36,000. GF Fund Management CO. LTD. acquired a new stake in Edgewise Therapeutics during the fourth quarter worth about $53,000. Aquatic Capital Management LLC acquired a new stake in Edgewise Therapeutics during the fourth quarter worth about $77,000. Tower Research Capital LLC TRC increased its holdings in Edgewise Therapeutics by 1,097.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,676 shares of the company's stock valued at $98,000 after buying an additional 3,369 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Edgewise Therapeutics in the 4th quarter valued at approximately $182,000.

Edgewise Therapeutics Stock Performance

Shares of EWTX traded down $0.18 during trading hours on Friday, reaching $12.77. The stock had a trading volume of 214,757 shares, compared to its average volume of 1,252,373. Edgewise Therapeutics, Inc. has a 12 month low of $10.60 and a 12 month high of $38.12. The stock has a market capitalization of $1.34 billion, a PE ratio of -8.24 and a beta of 0.26. The company's 50-day moving average is $14.06 and its two-hundred day moving average is $18.29.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. Equities analysts anticipate that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EWTX has been the subject of a number of recent analyst reports. Guggenheim began coverage on shares of Edgewise Therapeutics in a report on Wednesday, April 30th. They set a "buy" rating and a $41.00 price target for the company. Wedbush restated an "outperform" rating and set a $43.00 target price on shares of Edgewise Therapeutics in a research note on Monday, April 21st. Raymond James Financial began coverage on Edgewise Therapeutics in a report on Wednesday, July 30th. They issued a "strong-buy" rating and a $46.00 target price on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $48.00 price target on shares of Edgewise Therapeutics in a research note on Thursday, June 5th. Finally, HC Wainwright began coverage on Edgewise Therapeutics in a research report on Monday, June 30th. They set a "buy" rating and a $42.00 price objective for the company. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Edgewise Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $40.55.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.